To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Efidac 24 Combination Cold/Allergy Medication Cleared by FDA URL: http://www.pslgroup.com/dg/7666.htm Doctor's Guide April 3, 1996
PALO ALTO, Calif., April 3, 1996 -- ALZA Corporation (NYSE: AZA) today announced that Efidac 24(R) Pseudoephedrine/Brompheniramine, the first over-the-counter (OTC) 24-hour nasal decongestant/antihistamine combination product, has been cleared for marketing by the U.S. Food and Drug Administration. Efidac 24(R) Pseudoephedrine/Brompheniramine utilizes ALZA's proprietary OROS(R) oral controlled-release technology to deliver the drugs pseudoephedrine hydrochloride and brompheniramine maleate for 24 hours, providing temporary relief of nasal congestion due to the common cold, hay fever, or other upper respiratory allergies associated with sinusitis, and temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or other upper respiratory allergies. Efidac 24(R) Pseudoephedrine/Brompheniramine was developed by ALZA on behalf of the former ALZA's OROS(R) Products Limited Partnership. Ciba Self-Medication, Inc. holds U.S. marketing rights to the product. Launch plans have not been disclosed. Efidac 24(R) Pseudoephedrine/Brompheniramine is the third product to be cleared for marketing of a group of OROS(R) cold/allergy/sinus products based on ALZA's OROS(R) technology. Efidac 24(R) Pseudoephedrine, an OTC 24-hour nasal decongestant launched in 1993, was the first of these products to be cleared for marketing. Efidac 24(R) Chlorpheniramine, an OTC 24-hour antihistamine allergy medication, was introduced in the U.S. in the spring of 1995. Efidac 24(R) Pseudoephedrine and Efidac 24(R) Chlorpheniramine are manufactured by ALZA and marketed in the U.S. by Ciba Self-Medication under an agreement with ALZA . ALZA Corporation, headquartered in Palo Alto, California, is a leader in the development and commercialization of innovative pharmaceutical products using advanced drug delivery technologies to add medical and economic value to drug therapies. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.